Back to search results

Stereotactic Radiosurgery for Lung Cancer That Has Spread to the Brain

This study is looking at Stereotactic Radiosurgery (SRS) to treat people with small cell lung cancer that has spread to the brain (brain metastases). SRS is a type of radiation treatment. To join, you must have a diagnosis of small cell lung cancer, up to 20 brain metastases, be 18 or older, and have a good performance status (meaning you can do most daily activities). All participants will receive standard SRS treatment and will also have a lumbar puncture (spinal tap) to collect cerebrospinal fluid. The main goal is to see how long people live after treatment, measured at 6 months. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 62 participants. It is a single-arm study, meaning all participants receive the same treatment.
What's involved
You would undergo a CT simulation and an MRI for treatment planning, followed by Stereotactic Radiosurgery. You would also have a lumbar puncture (spinal tap) at the start of the study.
Compensation
Not stated in the trial record.
Follow-up
The study measures overall survival at 6 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05419076

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~62 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Stereotactic RadiosurgeryCerebrospinal fluid collection

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall survival
Measured over 6 months

Conditions

Lung Cancer
Lung Cancer Metastatic
Brain Metastases
Brain Metastases, Adult
Small-cell Lung Cancer
Small Cell Lung Carcinoma

Explore related trials

Lung Small Cell CarcinomaMetastatic Malignant Neoplasm in the Brain

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Luke Pike, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Luke Pike, MD
[email protected]
201-775-7604
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologic diagnosis of small cell lung cancer
Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI
Age 18 and above
Performance status KPS 60-100/ECOG 0-2
Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment
The patient or legally authorized representative is able to provide informed consent

Exclusion

Unable to undergo contrast-enhanced MRI brain
Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine
Pregnant or lactating women
Prior brain-directed radiotherapy
Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET/CT imaging, no more than 3 months before study enrollment

What this trial measures

  • Overall survival6 months

    The primary endpoint of this study is the rate of overall survival at 6 months, with time measured from the start of SRS treatment. Participants will be censored at the date of last follow up or the last date the participant was known to be alive.